期刊文献+

帕金森病模型小鼠脑内5-羟色胺转运蛋白和5-羟色胺1A受体的变化

Changes of the serotonin transporter and 5-HT_(1A) receptor in brain of MPTP-induced Parkinson's disease mice models
下载PDF
导出
摘要 目的观察帕金森病(PD)模型小鼠脑内5-羟色胺转运蛋白(SERT)和5-羟色胺1A 受体(5-HT_(1A))的变化。方法 8周龄雄性 C57BL/6小鼠,腹腔注射1-甲基4-苯基-1,2,3,6-四氢吡啶(MPTP),建立 PD 模型小鼠,每组各9只。高剂量组(按体重注射80 mg/kg,每2 h 注射20 mg/kg 1次,共4次);低剂量组20 mg/kg 单次注射;同时设生理盐水对照组。第11天用 ^(131)I-2-((2-((二甲基胺基)甲基)苯基)硫)-5-碘苯胺(ADAM)、4-^(131)I-N-2-[1-(2-甲氧基苯基)-1-哌嗪基乙基]-N-2-吡啶基-苯甲酰胺(^(131)I-MPPI)进行小鼠脑内放射自显影、生物学分布实验,测定 SERT 和5-HT_(1A)的相对含量,并用免疫组织化学法测定 SERT 及5-HT_(1A)阳性细胞数。结果与对照组相比,模型鼠脑内 SERT和5-HT_(1A)的含量减少,且 MPTP 用量越高减少得越多。放射自显影结果示高剂量组较对照组 SERT 和5-HT_(1A)含量分别减少67%和75%,脑内分布实验示两者分别减少34%和52%,免疫组织化学测定示分别减少41.3%和46.3%。结论 MPTP 对多巴胺神经元的损伤不是特异性的,在 PD 模型小鼠脑中5-HT 神经系统也受到 MPTP 的毒性损伤,SERT 和5-HT_(1A)的相对含量呈不同程度的下调。 Objective To observe the changes of serotonin transporter (SERT) and serotonin 1A receptor (5-HT1A) in brain of 1-methy-4-phenyl-1, 2, 3, 6-tetrahy-dropyridine (MPTP)-induced Parkinson's disease (PD) mice models. Methods Eight-week-old male C57BL/6 mice were used. High dose group ( n = 9 ) received a total dose 80 mg/kg MPTP intraperitoneally ( four injections of 20 mg/kg at 2 h intervals) while low dose group (n=9) was given a single injection of 20 mg/kg, and saline injection was used as control. Ten days after last injection of MPTP or saline (control), the mice were sacrificed for in vivo autoradiography, immunohistochemistry and biodistribution studies. Results Binding of SERT and 5- HT1A in brain of mice models as determined by ^131I-2-( (2-((dimethylamino) methyl) phenyl) thio)-5-iodophenylamine ( ADAM ) and ^131I-4-iodo-N-2-[ 1-( 2-methoxyphenyl )-1-piperazinyl ethyl ] -N-2-pridinyl-benzamine (MPPI) respectively was decreased with the increased doses of MPTP. Autoradiography of the brain of mice models showed significant reduction of SERT and 5-HT1A in 80 mg/kg MPTP-treated mice as compared with the control group. Immunohistochemical studies also showed that SERT and 5-HT1A decreasd by 41.3% and 46.3% respectively. Furthermore, biodistribution studies exhibited a 34% reduction in SERT and a 52% in 5-HT1A respectively. Conclusions There is significant decrease of both the SERT and 5HT1A receptor in brain of MPTP-induced PD mice models. The observed down-regnlation in both receptors suggests that MPTP do not specifically injure the dopamine neurons, and it down-regnlate both the dopamine and 5-HT neurons in different magnitude.
出处 《中华核医学杂志》 CAS CSCD 北大核心 2006年第4期216-218,共3页 Chinese Journal of Nuclear Medicine
基金 江苏省医学重点人才基金(RC2002068) 江苏省"六大人才高峰"基金(2003-07)
关键词 帕金森病 放射自显影术 载体蛋白质类 受体 血清素 小鼠 Parkinson disease Brain Autoradiography Carrier proteins Receptors, serotonin Mice
  • 相关文献

参考文献7

  • 1Zesiewiez TA, Gold M, Chari G, et al. Current issues in depression in Parkinson's disease. Am J Geriatr Psychiatry, 1999, 7 : 110-118.
  • 2Cummings JL, Masterman DL. Depression in patients with Parkinson's disease. Int J Geriatr Psychiatry, 1999, 14: 711-718.
  • 3Beal M. Experimental models of Parkinson' s disease. Nature, 2001,5 : 325-332.
  • 4吴春英,林祥通,陆春雄,蒋泉福,邹美芬,陈正平,王颂佩,李晓敏,张同兴,朱钧清.5-羟色胺转运蛋白显像剂~*I-ADAM临床前药理研究[J].中华核医学杂志,2004,24(5):298-301. 被引量:1
  • 5吴春英,林祥通,陆春雄,邹美芬,张政伟,刘平,薛方平,陈正平,蒋泉福,傅榕赓,王颂佩,张同兴,李晓敏,朱钧清.5-HT_(1A)受体显像剂^(18)F-MPPF的制备及其生物学特性评价[J].中华核医学杂志,2004,24(2):121-123. 被引量:4
  • 6Kerenyi L, Rieaurte GA, Schretlen DJ, et al. Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol, 2003, 60 : 1223-1229.
  • 7Doder M,Rabiner A, Turjanski N, et al. Tremor in Parkinson's disease and serotonergic dysfunction: an ^11C-WAY 100635 PET study.Neurology, 2003,60:601-605.

二级参考文献11

  • 1.异常毒性检查法[A]..中华人民共和国药典(2000年版)二部[C].,.附录ⅪC:附录75.
  • 2Staley JK, Maltson RT, Innis RB. Imaging of the serotonergic system:interactions of neuroanatomical and functional abnormalities of depression.Biol Psychiatry, 1998, 44: 534-549.
  • 3Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem, 1994, 40: 288-295.
  • 4Kauppinen TA, Bergstrom KA, Heikman P, et al. Biodistribution and radiation dosimetry of 123I-ADAM in healthy human subjects: preliminary results. Eur J Nucl Med Mol Imaging, 2003, 30: 132-136.
  • 5Lin KJ, Ye XX, Yen TC, et al. Biodistribution study of 123I-ADAM in mice: correlation with whole body autoradiography. Nucl Med Biol,2002, 29: 643-650.
  • 6Choi SR, Hou C, Oya S, et al. Selective in vitro and in vivo binding of 125I-ADAM to serotonin transporters in rat brain. Synapse, 2000, 38:403-412.
  • 7异常毒性检查法.中华人民共和国药典(2000年版)二部.附录75.
  • 8Oya S, Chol SR, Hou C, et al. 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodo phenylamine(ADAM): an improved serotonin transporter ligand. Nucl Med Biol, 2000, 27: 249-254.
  • 9Acton D, Mu M, Karl P, et al. Single-photon emission tomography imaging of serotonin transporters in the nonhuman primate brain with 123I-ODAM. Eur J Nucl Med, 1999, 26:1359-1362.
  • 10Fujita J, Takatoku K, Matoba Y, et al. Differential kinetics of 123I-β-CIT binding to dopamine and serotonin transporters. Eur J Nucl Med, 1996,23: 431-436.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部